Biotts

Biotts S.A. is a Polish-American biotechnology company focused on developing proprietary drug formulations, particularly in the fields of oncology, diabetology, and autoimmune diseases. Founded in 2018 by Dr. Konrad Sierzputowski and Dr. Paweł Biernat, the company leverages their combined expertise in chemistry and biotechnology to address challenges in drug delivery. Dr. Sierzputowski's background includes work at the Wroclaw Research Center EIT+, while Dr. Biernat has experience from the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, providing a strong scientific foundation for the company's endeavors.

The core of Biotts' strategy is its proprietary MTC-Y (Multifunctional Transdermal Carrier-Y) technology, a universal transdermal therapeutic system. This platform is designed to significantly enhance the bioavailability of active pharmaceutical ingredients (APIs) by enabling them to penetrate the skin and reach underlying soft tissues and even bones. A key feature of this technology is the ability to reduce the required therapeutic dose of a drug, which in turn can lower the incidence and severity of side effects for patients. The business model centers on developing drug-device combination products and then out-licensing them to major pharmaceutical partners for final development, regulatory approval, and commercialization. Biotts' pipeline includes a lead candidate, BIOTTS-234, an oncology drug for treating skin cancers like melanoma and basal cell carcinoma, which has shown promise in preclinical studies for targeted, local delivery. Another significant project is BIOTTS-PAIN-021, a transdermal solution for acute and chronic pain management.

By focusing on reformulating known active substances with its MTC-Y carrier, Biotts aims to create products with improved therapeutic profiles and new patent protection. This approach allows the company to operate in the vast markets for oncology and pain management by offering a differentiated delivery method. The company's system is versatile, allowing for the transport of single or multiple active substances, opening possibilities for creating combination therapies within a single transdermal patch.

Keywords: biotechnology, drug delivery, transdermal systems, oncology, diabetology, pain management, pharmaceutical formulations, MTC-Y technology, drug reformulation, out-licensing